April 4, 2025 01:25 PM EDT
China
Pharma
Manufacturing

Chi­na's re­tal­ia­to­ry tar­iffs on US could mean more head­winds for drug­mak­ers

Anna Brown

News Reporter

Chi­na’s an­nounce­ment of 34% tar­iffs on all US im­ports — a re­tal­i­a­tion against US tar­iffs that were an­nounced this week — could cre­ate more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Ther­mo Fish­er buck­les up for US-Chi­na trade war, bud­gets $2B to ease im­pact

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times